Announces Investment Banking Arm
Sydney, Aug 19, 2015 AEST (ABN Newswire) - iQ3Corp Ltd (
ASX:IQ3) today announced that through its fully owned subsidiary in the U.S., iQ Capital LLC, it is applying to obtain the necessary licenses to operate an investment banking business dedicated to life sciences.
For this reason it has mandated its advisors to commence regulatory filings with a scope to offer the following financial services:
Debt or Equity Offerings Through Public or Private Placement
> Pricing of securities in the debt and equity offerings
> Origination, which deals with equity capital markets and debt capital markets
> Underwriting
> Marketing
> Structuring
> Syndication
> Managing the allocation and stabilisation activities of offerings
Mergers, Acquisitions and Financial Restructuring
> Tender offers
> Selling assets
> Corporate reorganisation or divestitures
> Transactions involving business combinations, which include rendering opinions solvency and fairness opinions
General Broker and Dealer Services
The investment bank - iQ Capital - aims to realise cross border arbitrage between Australian biotech assets and American biotechnology institutional investors.
CEO of iQ3Corp., Dr. George Syrmalis - who previously founded and led one of Europe's first and foremost Biotechnology companies, The Bionuclear Group SA - says, "this represents a major milestone for our investors, the biotech industry, our team and the people we work with."
"I believe this is an extremely strategic and innovative position to take within the industry, and demonstrates our whole-hearted commitment towards developing the medicines of the future."
iQ3Corp. expects iQ Capital to gradually commence operational activity in approximately 90 days and fulfill its regulatory commitments within six to nine months.
About iQ3Corp Ltd
iQ3Corp Ltd (ASX:IQ3) is the world's first specialised life science corporate financial advisory and asset management firm.
iQ3Corp capitalises on its relationship with The iQ Group Global Companies and other industry participants such as academic institutions, financial market participants and other Life Science industry bodies, to provide a turnkey solution for capital raising from corporate inception to the capital markets.
iQ3 provides advice to life science companies on mergers and acquisitions, strategic matters, restructuring and capital structure, capital raising and corporate finance, as well as asset management services to corporations, partnerships, institutions, governments, and individuals.
| ||
|
